Abstract: This disclosure relates to methods for detecting a level of expression of one or more genes (or proteins) in a subject having or suspected of having cancer, and optionally treating the subject with an adenosine pathway antagonist, for example an adenosine A2A receptor (ADORA2A) antagonist, to treat the cancer.

Abstract: Provided herein are, inter alia, humanized 1E9 antibodies capable of binding CD73. The humanized antibodies are useful for the treatment of cancer. Further provided are nucleic acids encoding humanized 1E9 antibodies and methods of inhibiting cell proliferation using the humanized antibodies provided herein.

Abstract: Provided herein are, inter alia, anti-CD73 antibodies and methods of using the same. The antibodies provided include amino acid substitution embodiments affecting the antibody glycosylation state. The antibodies provided herein are, inter alia, useful for the treatment of cancer and effective for inhibition of CD73 activity.

Abstract: A honeycomb body having a honeycomb structure and a peripheral skin, the honeycomb structure having walls defining a plurality of cells including peripheral cells disposed directly adjacent to the peripheral skin. One or more of the peripheral cells is at least partially defined by a first wall surface, a second wall surface, and a skin surface portion extending between the first wall surface and the second wall surface. A continuously-varying radius extends from a first tangent to the first wall surface along the skin surface portion and to a second tangent to the second wall surface. Other honeycomb bodies, structures, and extrusion dies for forming honeycomb structures are disclosed.

Abstract: Provided herein are, inter alia, methods of treating a cancer tumor in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of an adenosine A2A receptor antagonist, wherein the subject comprises an elevated level of CD8+ tumor infiltrating lymphocytes relative to a control, the subject comprises an elevated level of T-effector gene signature relative to a control, the subject comprises an increased cancer tumor T cell receptor diversity or blood T cell receptor diversity relative to a control, the cancer tumor comprises an elevated level of PD-L1 relative to a control, and/or the cancer tumor or the blood of the subject comprises an elevated level of CD73 relative to a control. Further provided are, inter alia, methods for determining whether a subject is likely to, is, or has responded to anti-cancer therapy comprising an A2A receptor antagonist.

Abstract: Extrusion dies and methods of manufacturing extrusions dies, the extrusion die including a first plate and a second plate. The first plate has first upstream and downstream surfaces. A first material of the first plate has a first elastic modulus. The first plate includes pins formed between a plurality of slots. The pins and slots define a discharge face for the extrusion die at the first downstream surface of the first plate. The second plate has second upstream and downstream surfaces. The second plate is joined at the second downstream surface to the first upstream surface of the first plate. A second material of the second plate has a second elastic modulus. The second elastic modulus is greater than the first elastic modulus. A plurality of feed holes extend from the second upstream surface of the second plate through the extrusion die into communication with the slots.

Abstract: Provided herein are, inter alia, methods of treating cancer by administering to a subject a therapeutically effective amount of an adenosine-A2A (A2A) receptor antagonist or a combination of an adenosine-A2A (A2A) receptor antagonist and a programmed cell death protein 1 (PD-1) signaling pathway inhibitor. Further provided are pharmaceutical compositions including an A2A receptor antagonist, a PD-1 signaling pathway inhibitor and a pharmaceutically acceptable excipient. Further provided are methods of detecting cellular effects, for example expression of pCREB, before, after or during adenosine receptor antagonist treatment.

Abstract: A method includes receiving fault management data and service quality management data from an integrated feedback control loop, wherein a first set of faults in the fault management data is correlated with service quality management data if a root cause of the first set of faults is known and wherein a second set of faults in the fault management data are categorized as silent faults if no root cause of the second faults is known, The silent faults in the fault management are correlated with the service quality management data. The disclosure includes prioritizing analysis of the silent faults that affect the service quality management data, and prioritizing repair of faults in the fault management data that affect the service quality management data.

Abstract: An orthosis is fitted to a body joint, in a preferred embodiment the equine fetlock, by locating the center of rotation (COR) of the joint; measuring the bones comprising the joint at points located with respect to the COR; selecting the appropriate orthosis from a selection of models thereof; and custom-fitting the orthosis to the individual by heating it to soften a layer of thermoformable foam on the interior of the orthosis and clamping the orthosis in place over the body joint. A kit of tools for performing the measurements is disclosed, as are a method for location of the COR of the body joint by palpation and a preferred heater.

Abstract: A coated ceramic honeycomb body comprising a honeycomb structure comprising a matrix of intersecting porous walls forming a plurality of axially-extending channels, at least some of the plurality of axially-extending channels being plugged to form inlet channels and outlet channels, wherein a total surface area of the outlet channels is greater than a total surface area of the inlet channels, and wherein a catalyst is preferentially located within the outlet channels, and preferentially disposed on non-filtration walls of the outlet channels. Methods and apparatus configured to preferentially apply a catalyst-containing slurry to the outlet channels and non-filtration walls are provided, as are other aspects.

Abstract: The disclosure relates to technology for an apparatus having a current conveyer comprising a first stage having a first differential input, and a second stage having a second differential input. The first and second stages are configured to operate in a push-pull mode to provide an output signal at a current conveyer output between the first stage and the second stage. The apparatus has a first frequency mixer configured to generate a first mixer signal based on an input signal and an oscillator signal having a first frequency. The first frequency mixer is configured to provide the first mixer signal to the first differential input. The apparatus has a second frequency mixer configured to generate a second mixer signal based on the input signal and a second oscillator signal having the first frequency. The second frequency mixer is configured to provide the second mixer signal to the second differential input.

Abstract: Disclosed herein is an automated fiber placement system that comprises a robot, an end effector, and a creel assembly that is coupled to the robot and movable with the robot. The creel assembly comprises a spool of a tow and a tow tensioner. The tow tensioner comprises an arm assembly that is pivotable toward and away from a tow direction between a forward position and a rearward position, inclusive, and configured to secure the tow from the spool as the tow unwinds from the spool and moves in the tow direction. The tow tensioner also comprises a biasing member that is coupled to the arm assembly and configured to bias the arm assembly into a neutral position between the forward position and the rearward position. The tow tensioner additionally comprises a potentiometer that is coupled to the arm assembly and configured to detect a position of the arm assembly.

Abstract: A method includes collecting operational data from a system, segregating the data into a first component comprising one or more service quality anomalies and a second component comprising one or more network-based events, correlating the first component and the second component to determine whether the one or more network-based events have an impact on service quality, and prioritizing a resolution of the network-based events that have an impact on service quality.

Abstract: There is provided a method for determining a quality of an abrasive surface preparation of a composite surface, prior to the composite surface undergoing a post-processing operation. The method includes fabricating levels of abrasive surface preparation standards for a reference composite surface; using a surface analysis tool in the form of an ohm meter, to create target values for quantifying the levels; and measuring, with the surface analysis tool, one or more abrasive surface preparation locations on the composite surface of a test composite structure, to measure one or more of, electrical resistance and surface resistivity, of the composite surface, to obtain test result measurement(s). The method further includes comparing the test result measurement(s) to the levels, to obtain test result level(s); determining if the test result level(s) meet the target value(s); and determining whether the composite surface is acceptable to proceed with the post-processing operation.

Abstract: Provided herein are, inter alia, methods of treating cancer by administering to a subject a therapeutically effective amount of an adenosine-A2A(A2A) receptor antagonist or a combination of an adenosine-A2A(A2A) receptor antagonist and a programmed cell death protein 1(PD-1) signaling pathway inhibitor. Further provided are pharmaceutical compositions including an A2A receptor antagonist, a PD-1 signaling pathway inhibitor and a pharmaceutically acceptable excipient. Further provided are methods of detecting cellular effects, for example expression of pCREB, before, after or during adenosine receptor antagonist treatment.

Abstract: A honeycomb body (300) including a plurality of radially-extending walls (322) intersecting with a plurality of circumferentially-extending walls (324), the plurality of radially-extending walls (322) and the plurality of circumferentially-extending walls (324) form a plurality of circumferential zones (334A, 334B, 334C) of cells (308). The plurality of circumferential zones (334A, 334B, 334C) of cells (308) includes a first zone of cells (334A) including two or more first rings of cells (330) and having a first cell density, and a second zone of cells (334B) including two or more rings of cells (330) having varying cell densities across the two or more rings of cells. Other structures and extrusion dies are disclosed.

Abstract: Provided herein are, inter alia, methods for treating cancer in subjects expressing elevated levels of adenosine A2A receptors, and optionally further expressing elevated levels of CD73 and/or PD-L1, by administering adenosine pathway inhibitors.

Abstract: Provided herein, inter alia, are compounds and methods for modulating Bruton's Tyrosine Kinase.

Abstract: There is disclosed a tool kit including differently sized and shaped tongue-cleaning working tips. The working tips generally include a distal working blade for engagement with the surface of the tongue. In some embodiments, the distal working blades are planar and may include one or more bends between planar sections or portions. In other embodiments of the tongue-cleaning working tips, the working blades are curved. The tongue-cleaning working tips may optionally include a proximal mounting stem extending proximally from the distal working blade to allow for better access to certain regions of the tongue. Additionally, the distal working blades of the tongue-cleaning working tips may be tapered to further reach desired areas of the tongue.

Abstract: A method includes collecting operational data from a system, segregating the data into a first component comprising one or more service quality anomalies and a second component comprising one or more network-based events, correlating the first component and the second component to determine whether the one or more network-based events have an impact on service quality, and prioritizing a resolution of the network-based events that have an impact on service quality.